All In Biotech

Drug Trial Radar · NCT03078075

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

NIDA (National Institute on Drug Abuse) CTN (Clinical Trials Network) Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 403 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

403

Actual

Start

May 5, 2017

Primary completion

Jul 3, 2019

Study completion Jul 25, 2019

Sponsor

Lead sponsor
University of Texas Southwestern Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC
First posted
Mar 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.

Conditions

  • Methamphetamine Use Disorder

Interventions

  • Naltrexone: Vivitrol®Drug

    Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks

  • Placebo (PLB) InjectableDrug

    Placebo: 4 intramuscular injections administered every 3 weeks

  • Bupropion: Wellbutrin XL®Drug

    Bupropion: 450 mg oral dose daily

  • Placebo (PLB) OralDrug

    Placebo: once-daily oral placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Response During Medication Phase at Stage 1Time frame: At week 6
  2. Number of Participants in Placebo Arm With Treatment Response During Medication Phase at Stage 2Time frame: At week 12
  3. Number of Participants With Treatment Response During Medication Phase at Stage 1 (by Race)Time frame: At week 6
  4. Number of Participants With Treatment Response During Medication Phase at Stage 1 (by Ethnicity)Time frame: At Week 6
  5. Number of Participants With Treatment Response During Medication Phase at Stage 1 (by Sex)Time frame: At week 6
  6. Number of Participants With Treatment Response During Medication Phase at Stage 2 (by Race)Time frame: At week 12
  7. Number of Participants With Treatment Response During Medication Phase at Stage 2 (by Ethnicity)Time frame: at Week 12
  8. Number of Participants With Treatment Response During Medication Phase at Stage 2 (by Sex)Time frame: At week 12

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA) Center for Behavioral Addiction Medicine (CBAM)

    Los Angeles, California

  • Substance Use Research Unit (SURU) at the San Francisco Dept. of Public Health

    San Francisco, California

  • Hennepin County Medical Center- Berman Center for Research

    Minneapolis, Minnesota

  • New York State Psychiatric Institute (NYSPI)- Substance Use Research Center (SURC)

    New York, New York

  • CODA, Inc.

    Portland, Oregon

  • Behavioral Health Services (BHS) of Pickens County

    Pickens, South Carolina

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • University of Texas Health Science Center - Center for Neurobehavioral Research on Addiction (CNRA)

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.